In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...

A flu vaccine that harnesses the messenger RNA technology that ended the COVID-19 pandemic appears increasingly likely, ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported in the ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published ...

Good morning. Because the flu shot is locked in six months early, it missed the strain now circulating through Canada – more ...

Researchers at MIT have just developed a new lipid nanoparticle that super-enhances the effectiveness of the mRNA vaccine in ...

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

Pfizer's mRNA flu vaccine posts promising NEJM results. Dr. Todd Ellerin of South Shore Health discusses safety, side effects ...

Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in a Phase 3 ...

A newly developed mRNA-based flu vaccine is almost 35 per cent more effective against the most common form of influenza, ...